Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Headlines > Swiss biotech BioVersys gets $235 million valuation after completing flotation
    Headlines

    Swiss biotech BioVersys gets $235 million valuation after completing flotation

    Published by Global Banking & Finance Review®

    Posted on February 6, 2025

    2 min read

    Last updated: January 26, 2026

    Image of Kim Leadbeater addressing the media about proposed changes to the UK's assisted dying law, emphasizing the removal of High Court judge sign-off to enhance the legislative process.
    Lawmaker Kim Leadbeater discusses UK's assisted dying law changes - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationvaluationsBiotechinvestmentfinancial markets

    Quick Summary

    Swiss biotech BioVersys completes IPO, reaching a $235 million valuation. Funds will develop treatments for drug-resistant infections.

    BioVersys Achieves $235 Million Valuation Following IPO Completion

    ZURICH (Reuters) - Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million Swiss francs ($235.46 million).

    Just over 2.2 million shares were placed by the Basel-based company in the all-primary offering at 36 francs per share, it said on Thursday.

    Trading is due to start on Friday, with the stock expected to be included on the Swiss Performance Index on February 10.

    BioVersys researches and develops novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria.

    It raised 90 million francs from the IPO, which will used towards the development of its BV100 treatment for infections linked to ventilator-associated pneumonia and bloodstream infections.

    Some of the money will be used for its tuberculosis product alpibectir, which BioVersys is working on with GSK.

    CEO Marc Gitzinger said the IPO was the next stage in the company's growth strategy.

    "This support enables us to move full speed ahead with BV100 into the Phase 3 program, advance alpibectir into additional Phase 2 trials in collaboration with GSK and further progress our early stage pipeline," he said.

    ($1 = 0.9046 Swiss francs)

    (Reporting by John Revill; Editing by Bernadette Baum)

    Key Takeaways

    • •BioVersys completes IPO with a $235 million valuation.
    • •2.2 million shares placed at 36 francs each.
    • •Funds to develop BV100 and alpibectir treatments.
    • •CEO highlights growth strategy post-IPO.
    • •BioVersys collaborates with GSK on tuberculosis product.

    Frequently Asked Questions about Swiss biotech BioVersys gets $235 million valuation after completing flotation

    1What is BioVersys known for?

    BioVersys researches and develops novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria.

    2How much did BioVersys raise from its IPO?

    BioVersys raised 90 million francs from the IPO, which will be used towards the development of its BV100 treatment for infections.

    3What will the IPO funds be used for?

    The funds will be allocated to advance the BV100 treatment into Phase 3 trials and further develop the tuberculosis product alpibectir in collaboration with GSK.

    4When is BioVersys expected to start trading?

    Trading for BioVersys is due to start on Friday, with the stock expected to be included on the Swiss Performance Index on February 10.

    5What did CEO Marc Gitzinger say about the IPO?

    CEO Marc Gitzinger stated that the IPO was the next stage in the company's growth strategy, enabling them to move forward with their treatment programs.

    More from Headlines

    Explore more articles in the Headlines category

    Image for Exclusive-US plans initial payment towards billions owed to UN-envoy Waltz
    Exclusive-US plans initial payment towards billions owed to UN-envoy Waltz
    Image for Trump says good talks ongoing on Ukraine
    Trump says good talks ongoing on Ukraine
    Image for France to rally aid for Lebanon as it warns truce gains remain fragile
    France to rally aid for Lebanon as it warns truce gains remain fragile
    Image for Exclusive-US aims for March peace deal in Ukraine, quick elections, sources say
    Exclusive-US aims for March peace deal in Ukraine, quick elections, sources say
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Olympics-Italy's president takes the tram in video tribute to Milan transport
    Olympics-Italy's president takes the tram in video tribute to Milan transport
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for Exclusive-Bangladesh PM front-runner rejects unity government offer, says his party set to win
    Exclusive-Bangladesh PM front-runner rejects unity government offer, says his party set to win
    Image for Azerbaijan issues strong protest to Russia over lawmaker's comments on Karabakh trial
    Azerbaijan issues strong protest to Russia over lawmaker's comments on Karabakh trial
    Image for UK police search properties in probe into Mandelson over Epstein ties
    UK police search properties in probe into Mandelson over Epstein ties
    View All Headlines Posts
    Previous Headlines PostAstraZeneca CEO says company has no access to executive Wang, in detention in China
    Next Headlines PostKremlin says space agency needs to develop 'dynamically' after firing its boss